Ambrisentan

Ambrisentan


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
China
Payment Terms
Negotiable
Production method
Negotiable
Shipping / Lead Time
Negotiable / Negotiable
Keyword
active pharma ingredient, ambrisentan
Category
Pharmaceuticals

Tianjin Chase Sun Pharmaceutical Co., Ltd

Membership
BIZ
Country / Year Established
China China / 1996
Business type
Manufacturer
Verified Certificate

9

Product name Ambrisentan Certification -
Category Pharmaceuticals Ingredients -
Keyword active pharma ingredient , ambrisentan Unit Size -
Brand name - Unit Weigh -
origin China Stock -
Supply type - HS code -

Product Information

Ambrisentan

CAS Registry Number: 177036-94-1

CAS Name: (aS)-a-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-b-methoxy-b-phenylbenzenepropanoic acid

Molecular Formula: C22H22N2O4

Molecular Weight: 378.42

Percent Composition: C 69.83%, H 5.86%, N 7.40%, O 16.91%

Literature References: Nonpeptide endothelin ETA receptor antagonist. Prepn: H. Riechers et al., WO 9611914; eidem, US 5932730 (1996, 1998 both to BASF); H. Riechers et al., J. Med. Chem. 39, 2123 (1996). Pharmacology: H. Vatter et al., Clin. Neuropharmacol. 26, 73 (2003). Clinical evaluation in pulmonary arterial hypertension: N. Galié et al., J. Am. Coll. Cardiol. 46, 529 (2005). Review of development and therapeutic potential: G. E. Billman, Curr. Opin. Invest. s 3, 1483-1486 (2002).

 

Derivative Type: (±)-Form

CAS Registry Number: 713516-99-5

Properties: Crystals from diethylether, mp 190-191°.

Melting point: mp 190-191°

 

Therap-Cat: Antihypertensive.

Keywords: Antihypertensive; Endothelin Receptor Antagonist.

 

 

B2B Trade

Price (FOB) Negotiable transportation -
MOQ Negotiable Leadtime Negotiable
Payment Options Negotiable Shipping time Negotiable

Tianjin Chase Sun Pharmaceutical Co., Ltd

Country / Year Established
China China / 1996
Membership
BIZ
Business type
Manufacturer

9

President
Mr. Yao
Product Category
Antibiotic and Antimicrobial Agents,Blood System Agents,Cardiovascular Agents,Organic Intermediate,Pharmaceutical Intermediates
Year Established
1996
No. of Total Employees
1001-2000
Company introduction

 

Tianjin Chase Sun Pharmaceutical Co. Ltd was founded in 1996 and the joint-stock transformation was completed in 2000. In 2009, Chase Sun pharmaceutical was listed on the Shenzhen Stock Exchange and became the first group of national GEM listed companies, also called as the first of Tianjin. Stock code: 300026

In 2013, the company won top 100 comprehensive list of listing Corporation, the best venture growing company in Gold Bull Award 2013, the most investment value listed Company, top 20 of the most competitive pharmaceutical listed Company in China, and the top 10 management team award of 2013 Chinese GEM Listing Corporation.

Products: Xuebijing Injection (Modern Traditonal Chinese Medicine), Fasudil hydrochloride oral preparation; and anti-tumor, immunoregulation, Cardiovascular and cerebrovascular, Anaesthesia API and intermediates;


Technology transfer center of Chase Sun Pharma covers an area of 25,000 square meters with a total investment of 300 million Yuan. Technology transfer center possesses production lines for synthetic drugs, such a polusaccharide, peptides, anti-cancer drugs and production lines for large volume injection, small volume injection, freeze-dried powder and oral solid preparation.  Each line is constructed in accordance with the GMP Standard (2010 revision) and has a laboratory for comprehensive testing and analysis with a complete production quality control system. Technology transfer center is committed to providing the customers services of process development of APIs and the intermediates from pre-clinical to the industrialization.

 

Services (Product means API, intermediate and fine chemical)

1 Own product production, sales; GMP & Non GMP);

2 Product Contract Manufacturing;  GMP & Non GMP);

3: Product research and development, achievements transformation including pilot studies and scale-up trials for new preparation and new products;

4 Studies of controlling the conditions and process of production;

5:    Validation of the maturity of the technical;

6 Providing drugs for clinical trials and small batch production;

7 Technology research, pilot project and technology programs advising and services;

8 Drug registration advising and services;

 

 

Main Product

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat A new message arrives
from a business partner.

No Data

  • There is no data to load
  • Check out the My TK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more